GB9206757D0 - Novel peptide receptor ligands - Google Patents

Novel peptide receptor ligands

Info

Publication number
GB9206757D0
GB9206757D0 GB929206757A GB9206757A GB9206757D0 GB 9206757 D0 GB9206757 D0 GB 9206757D0 GB 929206757 A GB929206757 A GB 929206757A GB 9206757 A GB9206757 A GB 9206757A GB 9206757 D0 GB9206757 D0 GB 9206757D0
Authority
GB
United Kingdom
Prior art keywords
receptor ligands
peptide receptor
novel peptide
novel
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929206757A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Ferring BV
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd, Ferring BV filed Critical Yamanouchi Pharmaceutical Co Ltd
Priority to GB929206757A priority Critical patent/GB9206757D0/en
Publication of GB9206757D0 publication Critical patent/GB9206757D0/en
Priority to PCT/GB1993/000614 priority patent/WO1993020099A2/en
Priority to AU37645/93A priority patent/AU3764593A/en
Pending legal-status Critical Current

Links

GB929206757A 1992-03-27 1992-03-27 Novel peptide receptor ligands Pending GB9206757D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB929206757A GB9206757D0 (en) 1992-03-27 1992-03-27 Novel peptide receptor ligands
PCT/GB1993/000614 WO1993020099A2 (en) 1992-03-27 1993-03-25 Cck and/or gastrin receptor ligands
AU37645/93A AU3764593A (en) 1992-03-27 1993-03-25 CCK and/or gastrin receptor ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929206757A GB9206757D0 (en) 1992-03-27 1992-03-27 Novel peptide receptor ligands

Publications (1)

Publication Number Publication Date
GB9206757D0 true GB9206757D0 (en) 1992-05-13

Family

ID=10712996

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929206757A Pending GB9206757D0 (en) 1992-03-27 1992-03-27 Novel peptide receptor ligands

Country Status (3)

Country Link
AU (1) AU3764593A (en)
GB (1) GB9206757D0 (en)
WO (1) WO1993020099A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222178B1 (en) * 1993-08-10 2003-04-28 James Black Foundation Ltd. Gastrin and cck receptor ligands, preparation thereof and pharmaceutical compositions containing them
US5795907A (en) * 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
MX9709874A (en) 1995-06-06 1998-03-31 Pfizer Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors.
JP3314938B2 (en) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド Substituted N- (indole-2-carbonyl) -glycinamides and derivatives as glycogen phosphorylase inhibitors
KR100241643B1 (en) 1995-06-06 2000-03-02 디. 제이. 우드 Substituted N- (indole-2-carbonyl) -β-alanimamide and its derivatives for treating diabetes
GB9610974D0 (en) * 1996-05-24 1996-07-31 Zeneca Ltd Herbicides
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
ATE377586T1 (en) * 1997-12-23 2007-11-15 Inst Nat Sante Rech Med TRIPEPTIDYLPEPTIDASE INHIBITORS
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
EP1114822A3 (en) * 1998-06-03 2002-11-13 Cortech Inc. Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors
JP2004517028A (en) * 1998-06-03 2004-06-10 コーテック インコーポレーテッド Indole and tetrahydroisoquinoline containing .ALPHA.-ketooxadiazoles as serine protease inhibitors
NZ511018A (en) 1998-10-08 2003-09-26 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1158980B1 (en) 1998-12-18 2005-08-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035452A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140834A1 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6897234B2 (en) 1999-12-17 2005-05-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
SE0000382D0 (en) 2000-02-07 2000-02-07 Astrazeneca Ab New process
MXPA02010452A (en) 2000-05-11 2003-06-06 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues.
AU2001273129A1 (en) 2000-06-30 2002-01-14 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
ES2282647T3 (en) 2002-06-14 2007-10-16 MERCK & CO., INC. INHIBITORS OF MITOTIC CINESINE.
JP4377323B2 (en) 2002-06-14 2009-12-02 メルク エンド カムパニー インコーポレーテッド Mitotic kinesin inhibitor
ES2319429T3 (en) 2003-08-15 2009-05-07 MERCK & CO., INC. INHIBITORS OF MITOTIC CINESINE.
US7666862B2 (en) 2003-08-15 2010-02-23 Merck & Co., Inc. Mitotic Kinesin Inhibitors
WO2005017190A2 (en) 2003-08-15 2005-02-24 Merck & Co., Inc. Mitotic kinesin inhibitors
FR2876102A1 (en) * 2004-10-04 2006-04-07 Solvay ENANTIOPUR HETEROCYCLIC COMPOUND
JP5121346B2 (en) * 2007-08-07 2013-01-16 国立大学法人 長崎大学 Optically active proline ester derivative and method for producing N-formyl optically active proline derivative
CN102812003B (en) * 2009-12-18 2015-01-21 欧洲筛选有限公司 Pyrrolidine Or Thiazolidine Carboxylic Acid Derivatives, Pharmaceutical Composition And Methods For Use In Treating Metabolic Disordersas As Agonists Of G- Protein Coupled Receptor 43 (GPR43)
EA023259B1 (en) 2011-01-04 2016-05-31 Новартис Аг Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US9108951B2 (en) 2011-10-14 2015-08-18 Bristol-Myers Squibb Company Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
ES2625256T3 (en) 2011-10-14 2017-07-19 Bristol-Myers Squibb Company Tetrahydroisoquinoline compounds substituted as XIA factor inhibitors
IN2014CN02805A (en) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6155332B2 (en) 2012-06-28 2017-06-28 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
CN104640855B (en) 2012-06-28 2017-08-29 诺华股份有限公司 Complement is by way of conditioning agent and application thereof
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
KR102143257B1 (en) 2012-10-12 2020-08-10 브리스톨-마이어스 스큅 컴퍼니 Crystalline forms of a factor xia inhibitor
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
ES2712699T3 (en) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahydroisoquinolines containing substituted azoles as inhibitors of factor XIa
US9770435B2 (en) 2013-11-27 2017-09-26 Ogeda Sa Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
TWI688564B (en) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
AU2015223075A1 (en) 2014-02-25 2016-09-01 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of complement mediated disorders
CN107074821B (en) 2014-09-04 2020-05-22 百时美施贵宝公司 Diamide macrocycles as FXIA inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
ES2809208T3 (en) 2015-06-25 2021-03-03 Promega Corp Thienopyrrole compounds and uses thereof as luciferase inhibitors from Oplophorus
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
IL303696A (en) 2017-03-01 2023-08-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
MX2020003242A (en) 2017-09-22 2020-09-18 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors.
IL272667B (en) 2017-10-18 2022-09-01 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
WO2019102494A1 (en) 2017-11-24 2019-05-31 Jubilant Biosys Limited Heterocyclic compounds as prmt5 inhibitors
CN112105610B (en) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
KR20210093855A (en) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 Conformational forms of complement factor D inhibitors
WO2023164238A1 (en) * 2022-02-25 2023-08-31 Regents Of The University Of Minnesota Protease inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215297A3 (en) * 1985-08-14 1989-07-19 G.D. Searle & Co. Substituted dipeptide amides
EP0288965A2 (en) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptides with a phospholipase A2 inhibiting activity
CA1326108C (en) * 1988-04-12 1994-01-11 Sun Hyuk Kim Cck antagonists
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) * 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
CA2072981A1 (en) * 1990-02-09 1991-08-10 Jean-Dominique Bourzat N-phenyl n-acetamido glycinamides, their preparation and drugs holding same

Also Published As

Publication number Publication date
AU3764593A (en) 1993-11-08
WO1993020099A2 (en) 1993-10-14
WO1993020099A3 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
GB9206757D0 (en) Novel peptide receptor ligands
GB2269176B (en) Peptides
EP0515681A4 (en) Peptide compound
ZA928511B (en) Peptides
EP0448099A3 (en) Novel peptides
GB9226065D0 (en) Peptides
EP0568539A4 (en) Soluble mannose receptor peptides
GB9208428D0 (en) Synthetic polypeptides
ZA915978B (en) Peptides
ZW9093A1 (en) Synthetic polypeptides
ZA933867B (en) Peptide compounds
ZA931299B (en) Novel peptides
GB9211668D0 (en) Peptide compounds
GB9211675D0 (en) Peptide compounds
GB9211674D0 (en) Peptide compounds
GB9211676D0 (en) Peptide compounds
GB9226074D0 (en) Peptide
GB9005855D0 (en) Peptide compounds
GB9005854D0 (en) Peptide compounds
GB9001030D0 (en) Peptide compounds
ZA935126B (en) Peptides
GB9210074D0 (en) Peptides
GB9008361D0 (en) Modified peptide
GB9311273D0 (en) Synthetic polypeptides
GB9214663D0 (en) Synthetic polypeptides